TCRA Plan

Rh Immune Globulin has eradicated Rh Hemolytic Disease in the developed world. Half of the Rh Negative mothers in the world are **not receiving** RhIG protection. **140,000** Rh babies are dying every year. **60,000** are starting life brain damaged. WIRhE can resolve this crisis but only if funded with **$250 million** annually – very insecure funding, if not impossible, with regular philanthropy. TCRA is the only shot for these Rh babies. **WIRhE must be funded** with a **$10 billion** endowment to save **all** the Rh babies in the world in perpetuity.

A necessary realization upfront which you must accept is that the scale of TCRA high finance deal is truly enormous - **$1 trillion over 20 years, 99% profit before taxes** for TCRA shareholders. We are talking about net profits of a whole industry, not just the profits of one big company like Spacex. This huge TCRA deal is bold but entirely doable with standard high finance practices in the hands of **seven action parties**, each doing their own straightforward thing, hignly incentivized to act in their own interests.

TCRA is based on the enormous revenue stream of **$8.8 trillion** that the huge **$293 billion** global clinical lab industry will earn over the next **20** years. Clinical lab revenues are the most inelastic and assured revenues of any industry because **70%** of actionable medical care decisions are now based on clinical lab test results, which are fundamental in healthcare today.

Rather than a set of isolated roles, TCRA functions as a continuous flow of capital and judgment operating as **a closed-loop value chain** rather than a collection of isolated roles. TCRA requires that **all 7 action parties** see the whole picture, see their place, but do their thing independenty, converting uncertainty into realized outcomes. Understanding this structure clarifies the true incentives of all TCRA stakeholders, explains how risk is transformed into long-term returns. The closed loop follows this path: **Stakeholders → Foundations→ VC → Rh Club → Underwriters → Big 4 → TCRA→ to Stakeholders' returns**. No need for an Elon to pull it off.

The 5 action parties of TCRA: Big 4, Foundations, Venture **Capital**, **Rh Club, Underwriter Company**(s),

Big 4,

Once the BIG 4 install DLA in their client clinical labs worldwide, Using TCRA intellectual property, clinical labs will pay royalties to TCRA of **$1 trillion** over the next **20** years. These royalties, all profit before taxes for

TCRA shareholders, will be earned on an impregnable US and International patent portfolio that TCRA owns covering advanced dark clinical lab automation technology, DLA. Once the Big 4 announce their intention to install DLA globally, awesome **gain of value** for TCRA shares will create instant PV wealth of **$300 billion** will be created for TCRA shareholders, with investors clambering to buy TCRA shares.

This powerful oligopoly of four major companies, *Siemens, Roche, Abbott, and Danaher,* control the global clinical lab automation market. It's well within their power to employ TCRA intellectual property in the next generation of automated analyzers and impose **$1 trillion** royalties on clinical labs globally over the next **20** years. Owning **28%** of TCRA, **$280 billion** in royalties, all new **net profit before taxes,** will accrue to Big 4 and greatly reward their stock prices.

Though royalties on intellectual property by equipment manufacturers are normal in many industries, a royalty model paid by clinical labs that will generate **10x more royalties** has never been used before. Applying royalties to clinical test data revenue is feasible today for the first time because of the existence of TCRA's patent portfolio, the perfect IP for imposing royalties on clinical labs. Global clinical labs will pay royalties for using TCRA'S new patented Dark Lab Automation technology. With **80%** savings in labor costs clinical labs' cost structure will not increase from royalties. DLA will make clinical labs much more efficient. The patents that TCRA happens to own create an extraordinary return for all TCRA shareholders.

Post DLA announcements, the Big 4 will sell some TCRA shares to investor funds to fully fund DLA development and introduction in clinical labs worldwide.

Underwriter Company(s)
At the signing event, our underwriter companies, a top bank and PE firm, will be granted **8%** of TCRA, **$80 billion** of the royalties. They will have assembled a **$20 billion** fund with limited partners committed to invest **~$20 billion** to buy TCRA shares at ~**$100 billion** TCRA company value. This is a major discount from the market value for being the first money.

At the signing event our underwriter companies will see to the transfer of blocks of TCRA shares to the foundations, the Big 4, the VC firm, the Rh club members and the underwriters themselves.

At the signing event our underwriter companies will enable all TCRA shareholders to sell some TCRA shares to limited partner funds. **WIRhE will raise $10 billion cash**, **Foundations $1 billion each**, **Underwriter Companies $1 billion, Venture Capital $1 billion, Big 4 $4 billion, Rh Club $1 billion, TCI $3 billion.**

Will the LP investors feel comfortable with this much immediate return for the parties at the signing when they accept all the risk of the first **$20 billion** investment?

Foundations
The central challenge is our limited direct access to A-list decision-makers. The roles of the Rockefeller and Gates foundations—each receiving approximately **$250 billion in royalty participation**—will be to **convene, align, and contractually bind** all parties essential to the TCRA transaction. This includes ensuring that every stakeholder is fully briefed on the structure, economics, and urgency of the deal, with particular emphasis on the reality that **TCRA represents the only viable path forward for the 140,000 Rh babies**.

As part of this mandate, the foundations will **formally commit**, through binding agreements, to assemble and maintain the coalition required to close and execute the transaction. Following the public announcement, they will also participate in the TCRA share-sale program, liquidating a portion of their holdings to raise an immediate **$1 billion** each, thereby contractually anchoring their responsibility to see the deal through to completion.

Venture Capital
VC(s) will receive **$1 billion** in TCRA shares at the signing for recruiting Rh club members to donate to WIRhE immediately. Will assist Rh Club members in TCRA share sales post announcements. Will find investors for future rounds of TCRA sales.

Rh Club
The role of the Rh Club billionaire members is to use their enormous access and influence to make sure Big 4 executives and boards know that TCRA is the only shot to save the **140,000** Rh babies. Also to make sure Big 4 understand their own enormous financial and strategic benefits from engaging with TCRA.

Rh Club billionaires will be allocated ~**$1 billion** in TCRA shares at the signing if they have influenced Big 4 and/or if they each donate ~**$10 million** to WIRhE immediately. There are many Wall Street titans who would jump on being an Rh Club member if they knew about it.

An **Inauguration Day Signing Conference** is planned where all 5 parties will sign a contract based on a term sheet negotiated ahead of time. Once all parties sign the contract at the conference all measures ordained in the contract will be enacted automatically.

- Big 4 DLA announcements already drafted will go out
- TCRA share blocks will be transferred to all parties
- Limited partners will use already raised and committed funds to purchase allotted TCRA shares and complete payments.

TCRA brings huge benefits at the signing for all parties – **win-win-win-win-win** for everyone involved.